Navigation Links
The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
Date:1/31/2008

WORCESTER, Massachusetts, February 1 /PRNewswire/ --

- ENDORSE Global Findings Highlight the Need to Urgently Implement Hospital-Wide Strategies to Optimize VTE Management: Systematically Assess Patient Risk for VTE and Provide Appropriate Prophylaxis to Prevent VTE

ENDORSE multinational study (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) published today in the LANCET(1) demonstrates the high prevalence of patients at risk for VTE (according to the ACCP guidelines) in the world: 52% of hospitalized patients surveyed were at risk for VTE, corresponding to 64% of surgical patients and 42% of medical patients.

ENDORSE demonstrates as well, that recommended prophylaxis is only prescribed to 50% of at-risk patients throughout the world, corresponding to 59% of surgical and 40% of medical patients.

With more than 60,000 patients studied in more than 32 countries encompassing 6 continents the scope of ENDORSE is unprecedented. With a wide range of racial, social, economic and health care environment, ENDORSE gives a unique global and local picture about the extent of the hospitalized patient population at risk for VTE and how these patients are managed.

Doctor Fred Anderson, Director of the Center for Outcomes Research at the University of Massachusetts Medical School who conducted the study commented "ENDORSE shows that a substantial proportion of hospitalized patients are at risk for VTE in each of 32 participating countries. Despite these objective data that VTE risk is important on a global scale, the use of recommended prophylaxis is sub-optimal. This is a complex problem, which will require multiple solutions, including local and national programs of education, guideline development, increased reimbursement for prophylaxis, and addition of VTE prevention to the health-care agenda in every country."

VTE is a major public health issu
'/>"/>

SOURCE University of Massachusetts Medical School
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Lancet Publishes Vasogens ACCLAIM Results
2. Vasogens Research Published in European Journal of Neuroscience
3. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
4. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
5. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
6. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
7. Researchers outline structure of largest nonvirus particle ever crystallized
8. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
9. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  David Hardison, ... ConvergeHEALTH by Deloitte , has been elected chairman ... Standards Consortium, a non-profit working to establish common ... particularly as it relates to electronic health records. ... CDISC,s mission of collaborating with organizations across the ...
(Date:7/28/2014)... 28, 2014 Appistry, Inc. , ... bring the power of genomics to next-generation medicine, announced ... Pipeline Challenge . , Two Appistry staff will ... National Center for Genome Resources, and Mr. Neil Miller, ... of Kansas City. Rounding out the panel are Appistry’s ...
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
(Date:7/28/2014)... The National Model Aviation Museum, located at the ... announce that it has been granted full civilian museum ... Air Force. , The certification is the culmination of ... with an on-site inspection by Sarah Sessions, Museum Certification ... National Museum of the United States Air Force , ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... Inc.,(NASDAQ: ISOT ) ("IsoTis"), an orthobiologics company, today ... it called to approve,the acquisition of IsoTis by Integra ... an agreement and plan of merger,dated as of August ... held at 9 a.m. Pacific time,today. An insufficient number ...
... Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... for 2007 after the market closes on Tuesday, November ... 4:30 p.m. EST,1:30 p.m. PST, on the company,s website. ... to the Company,s website at, http://www.cvt.com and go ...
... to be initiated by end of 2007 -, ... BIIB ) and PDL BioPharma, Inc. (PDL) (Nasdaq: ... a significant reduction in new or,enlarged gadolinium-enhancing lesions when ... active relapsing multiple,sclerosis (MS). These data will be presented ...
Cached Biology Technology:IsoTis Adjourns Special Meeting to October 23, 2007 2IsoTis Adjourns Special Meeting to October 23, 2007 3IsoTis Adjourns Special Meeting to October 23, 2007 4CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6
(Date:7/28/2014)... The findings of a new study suggest two ways ... not work as well in obese women, compared to women ... are a one-size-fits-all method, researchers say, but as the population ... the pill works for obese women. Studies have consistently found ... the body, which may in turn affect how well the ...
(Date:7/28/2014)... hunter, but the target of his work consists of ... special methods and instruments. Benjamin Hause, an assistant research ... Kansas State University, recently published an article about one ... important find in the United States. , "We had ... it was," Hause said. "We used next-generation sequencing to ...
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are using ... varying flexibility that can be used as microscale models ... that "bead-spring" polymers, introduced as theory in the 1950s, ... required and should be of interest to materials scientists ... work led by Rice chemical and biomolecular engineer Sibani ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Seeing is bead-lieving 2
... 1, 2008, New York, NY) The Parkinson,s Disease Foundation ... its 2008-2009 International Research Grants and Fellowship Program (IRGFP). ... Parkinson,s scientists, chosen on April 11 from a group ... led by Stanley Fahn, M.D., PDF,s Scientific Director. ...
... Technology shows that coating a titanium implant with a ... growth around the implant and strengthens the attachment and ... "We designed a coating that specifically communicates with cells ... the implant," said Andrs Garca, professor and Woodruff Faculty ...
... Crop yield is highly dependent on soil plant-available water, ... up by plant roots. Quantitative determination of the maximum ... on soil samples remains challenging, especially at the scale ... water capacity for a field would be instrumental in ...
Cached Biology News:The Parkinson's Disease Foundation awards $950,000 in seed grants 2The Parkinson's Disease Foundation awards $950,000 in seed grants 3Researchers coat titanium with polymer to improve integration of joint replacements 2Researchers coat titanium with polymer to improve integration of joint replacements 3Where is your soil water? Crop yield has the answer 2
ChIP-GLAS kit for H10K-B microarray chips. Contains ChIP kit, GLAS kit, and hybridization kit. Additional reagents are required. Please see manual for details. Contains sufficient reagent for 20 reac...
BD BaculoGoldTM Transfection Kit 5 transfections...
...
...
Biology Products: